Kam Sprott

Deciphera Pharmaceuticals (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index1.5kcitations50works10.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(9), Gastrointestinal Tumor Research and Treatment(9), Lymphoma Diagnosis and Treatment(7), Gastric Cancer Management and Outcomes(7), DNA Repair Mechanisms(6)

Publications50 total

INSIGHT: A Phase III Trial of Ripretinib Versus Sunitinib in Patients with Advanced GIST with KIT Exon 11 and Exon 17/18 Mutations Who Were Previously Treated with Imatinib
Annals of Surgical Oncology·2025Open Access
INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.
Journal of Clinical Oncology·2025· 1 cited
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with <i>KIT</i> exon 11 + 17/18 mutations
Future Oncology·2024· 13 citedOpen Access
62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutations: ctDNA analysis from INTRIGUE
ESMO Open·2024Open Access
INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.
Journal of Clinical Oncology·2024· 2 cited
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Nature Medicine·2024· 47 citedOpen Access
Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.
Journal of Clinical Oncology·2023· 2 cited
INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring <i>KIT</i> exon 11 + 17 and/or 18 mutations.
Journal of Clinical Oncology·2023· 6 cited
Supplementary Data from DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer
2023Open Access
Data from DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer
2023Open Access
Data from DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer
2023Open Access
Supplementary Data from DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer
2023Open Access
Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.
Journal of Clinical Oncology·2023· 15 cited
Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial
Blood·2019· 1 cited
A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)
Blood·2019· 2 cited
Characterization and Validation of Antibodies for Immunohistochemical Staining of the Chemokine CXCL12
Journal of Histochemistry & Cytochemistry·2018· 4 citedOpen Access
Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMOTM Clinical Trial in iNHL
Blood·2018· 1 cited
Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study
Blood·2018· 2 cited
Abstract 613: X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma
Cancer Research·2018· 10 cited
The effect of duvelisib, a dual inhibitor of PI3K-δ,γ, on components of the tumor microenvironment in previously untreated follicular lymphoma.
Journal of Clinical Oncology·2018
page 1 of 3Next →

Frequent Co-authors

David T. Weaver(26), William E. Pierceall(9), Suzanne George(9), Sebastian Bauer(9), Michael C. Heinrich(8), Robin L. Jones(8), Matthew L. Sherman(8), Jean‐Yves Blay(8), Jonathan A. Pachter(8), Chunsheng Jiang(7), John Zalcberg(7), William M. Reichmann(7), Rodrigo Ruiz‐Soto(7), Hans Gelderblom(6), Michael Stocum(5), César Serrano(5), Neeta Somaiah(5), Brian M. Alexander(5), D. Allan Farrow(5), XiaoZhe Wang(5)